Tesamorelin for Weight Loss: What the Evidence Shows
What human and animal studies show about Tesamorelin for weight loss, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 34
- PubMed records, our ledger
- Animal studies
- 0
- PubMed records, our ledger
- Studies we summarised
- 10
- with an outcome for weight loss
Evidence for weight loss
Each row is an outcome related to weight loss from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Body composition, fatigue, sleep and function | Low-dose tesamorelin did not significantly change body composition, fatigue, sleep, physical performance, glucose tolerance or cognition. | Human controlled trialn = 22 | eNeurologicalSci 2026, PMID 42382101 |
| Skeletal muscle area and density | In responders (a clinically significant VAT decrease), tesamorelin increased trunk muscle area and density on CT. | Human RCT | The Journal of frailty & aging 2019, PMID 31237318 |
| Metabolic effect of VAT response | Tesamorelin patients with an 8% or greater VAT reduction had better triglycerides, adiponectin and glucose homeostasis than nonresponders over 52 weeks. | Human RCT | Clinical infectious diseases 2012, PMID 22495074 |
| VAT, triglycerides and CRP | Tesamorelin reduced visceral fat without changing subcutaneous fat and improved triglycerides, C-reactive protein and carotid intima-media thickness without worsening glucose. | Human RCTn = 60 | The Journal of clinical endocrinology and metabolism 2012, PMID 23015655 |
| IGF-I and body fat | IGF-1 rose 117% (staying within the physiological range) and percent body fat fell 7.4%. | Human RCTn = 152 | Archives of neurology 2012, PMID 22869065 |
| Visceral adipose tissue at 6 months | VAT fell 10.9% (21 cm2) with tesamorelin versus 0.6% (1 cm2) with placebo in the 6-month efficacy phase. | Human RCTn = 404 | Journal of acquired immune deficiency syndromes 2010, PMID 20101189 |
| Durability after stopping | VAT stayed about 18% lower in patients continuing for 12 months; gains over 6 months were rapidly lost after switching to placebo. | Human RCTn = 404 | Journal of acquired immune deficiency syndromes 2010, PMID 20101189 |
| VAT and triglycerides at 52 weeks | VAT change was sustained at -18% over 52 weeks, and triglycerides fell 51 mg/dl. | Human RCTn = 410 | AIDS 2008, PMID 18690162 |
| After discontinuation | Visceral fat returned after tesamorelin was stopped. | Human RCTn = 410 | AIDS 2008, PMID 18690162 |
| Visceral adipose tissue | Visceral adipose tissue fell 15.2% with tesamorelin and rose 5.0% with placebo by the end of treatment. | Human RCTn = 412 | The New England journal of medicine 2007, PMID 18057338 |
| Trunk fat | Trunk fat changed +0.8% with placebo, -4.6% with 1 mg and -9.2% with 2 mg. | Human RCTn = 61 | AIDS 2005, PMID 16052083 |
| Visceral adipose tissue | Pooled mean difference in visceral adipose tissue was -21.47 (95% CI -34.73 to -8.22) versus control. | Meta-analysisn = 909 | Journal of the International Association of Providers of AIDS Care 2026, PMID 42538058 |
PubMed records for Tesamorelin and weight loss: 34 human, 0 animal (search counts, not studies we reviewed). Grades follow our evidence scale.
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Other peptides people research for weight loss
All peptides for weight loss, comparedCommon questions
Does Tesamorelin help with weight loss?
The strongest study we summarise for weight loss is human rct evidence, across 10 studies with an outcome for weight loss. A trial result is not an approval; see the legal status.
Is Tesamorelin approved for weight loss?
Tesamorelin is FDA approved (Egrifta). Which conditions that approval covers is set by the label; use for anything else is off-label.
What is the best peptide for weight loss?
There is no single answer. Our weight loss overview compares each candidate by evidence grade and legal status rather than by popularity.
More on Tesamorelin
DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.
Sources
- 1The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
- 2The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
- 3Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012PMID 22495074Accessed 2 Oct 2026
- 4Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.The Journal of clinical endocrinology and metabolism · 2012PMID 23015655Accessed 2 Oct 2026
- 5Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.Archives of neurology · 2012PMID 22869065Accessed 2 Oct 2026
- 6Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.Journal of acquired immune deficiency syndromes (1999) · 2010PMID 20101189Accessed 2 Oct 2026
- 7Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.AIDS (London, England) · 2008PMID 18690162Accessed 2 Oct 2026
- 8Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
- 9A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.AIDS (London, England) · 2005PMID 16052083Accessed 2 Oct 2026
- 10Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.Journal of the International Association of Providers of AIDS Care · 2026PMID 42538058Accessed 2 Oct 2026
Found an error? Report a correction.